# Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis

> **NCT00263315** · PHASE2,PHASE3 · COMPLETED · sponsor: **Erasmus Medical Center** · enrollment: 320 (—)

## Conditions studied

- Aspergillosis

## Interventions

- **DRUG:** nebulised liposomal amphotericin B

## Key facts

- **NCT ID:** NCT00263315
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** 320 (—)
- **Last updated:** 2006-08-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00263315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00263315, "Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00263315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*